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This review reports on the latest progress in the synthesis of fullerenyl amino acids and related
derivatives, and categorises the molecules into functional types for different uses: these include
directly attached fullerenyl amino acids, fullerenyl N- and C-capping amino acids, and those amino
acids in which the [60]fullerene group is attached to the amino acid side chain. These first and last
mentioned derivatives have the potential to be incorporated into non-terminal positions of peptides.
The applications of these substrates, by integration into different biological and materials chemistry
programs, are also highlighted.

Introduction
A large portion of synthetic [60]fullerene chemistry is directed towards its functionalization, often
providing biologically active derivatives and molecules with applications in material science.1 The
impetus for such work was to exploit the physical properties of [60]fullerene (such as sensitization
of singlet oxygen and electron acceptor characteristics) and combine this with the properties of
biomolecules (water solubility and precise secondary and tertiary structure).1e,

2

For example,

[60]fullerene derivatives covalently linked to peptides and proteins has been the goal of a number of
research groups concerned with the application of [60]fullerene-peptide conjugates to biological
problems.3 It was anticipated that the addition of biologically active compounds to [60]fullerene in
a strict regioselective fashion would aid the activity and specificity of future therapies. From a
material science and a medicinal chemistry perspective, fullerenyl amino acids are important targets
potentially serving as central hubs in architecturally defined nanostructures or 3D-templates in drug
design.1e, 4 To date fullerenyl amino acids and peptide derivatives have been prepared by the initial
attachment of a handle to the fullerene followed by coupling to a protected amino acid or peptide.5
In recent times,1f, 5c the field has matured significantly such that there are many different types of
fullerenyl amino acids that can be categorised according to the properties of the amino acid itself,
allowing for a broader perspective of how they could be incorporated into different research

programs. This review not only reports on latest progress in the synthesis of fullerenyl amino acids
and related derivatives, but attempts to categorise the molecules into functional types for different
uses: these include directly attached fullerenyl amino acids, fullerenyl N- and C-capping amino
acids, and those amino acids in which the [60]fullerene group is attached to the amino acid side
chain. These first and last mentioned derivatives have the potential to be incorporated into nonterminal positions of peptides. The applications of these substrates by integration into different
biological and materials chemistry programs are then highlighted.

1 Synthesis of Derivatives with Fullerenyl Substituents Directly Substituted to
the Amino Acid α-Carbon
There are surprisingly few examples of fullerenyl amino acids that are direct analogues of α-amino
acids, i.e. the α-carbon is bonded directly to a C60 carbon atom. There are two examples of this type
of molecule, the well-established fullerenoprolines, and there are reports of protected versions of
amino acids whereby the fullerenyl substituent is directly coupled to the α-carbon.
Fullerenoproline derivatives
The first synthesis of α-substituted fullerenyl amino acids, the fullerenoprolines (Fpr) (4) was
achieved by the addition of azomethine ylides to [60]fullerene.6 The azomethine ylide intermediate
can be generated in two different ways, either via a thermal ring-opening of aziridines 1 or via
tautomerisation of iminium salts formed by the condensation of α-amino esters 2 with aldehydes 3
(Scheme 1). These reactions allow for a significant number of Fpr derivatives to be generated by
using different combinations of aldehydes and amino esters.

Scheme 1: The synthesis of fulleropyrrolidines 4 can be achieved by thermal addition of aziridines or iminium salts to
[60]fullerene.

Fpr analogues can be prepared with the pyrrolidine nitrogen protected (Scheme 2) or unprotected
(Scheme 3).7 Addition of the aziridine 5 to [60]fullerene under thermal conditions formed the

protected N-protected-Fpr 6. Subsequent treatment with TFA provided the secondary amine salt 7,
which could then be acylated with acetic anhydride to provide 8 (Scheme 2).7

Scheme 2: Synthesis of 8 was achieved through thermal addition of aziridine 5 to [60]fullerene.

To obtain more useful Fpr derivatives for peptide synthesis, the azomethine ylides, which are
generated in situ from the reaction of glycinate esters 9 and 10 with paraformaldehyde, can be
added to [60]fullerene to produce the free Fprs 11 and 12, respectively. These were relatively
unstable and had to be kept as dilute solutions in the dark.7 However, the amine group was readily
functionalized using standard acylation procedures with acid anhydrides and acid chlorides
(Scheme 3), to deliver diastereomeric mixtures of fullerenyl amino esters of the type 13.
Alternatively the amine 11 was protected as the N-Fmoc derivative 14, and then the tert-butyl ester
converted to the acid 15 by treatment with TFA. Subsequent coupling with ethyl L-alaninate under
EDCI/HOAt conditions afforded the diastereomers 16 and 17. The diastereomeric ratio of 13 was
determined by formation of the dioxopiperazines 18 and 19, thus eliminating the additional
complexity in characterization imposed by amide rotamers.7

Scheme 3: Synthesis of Fpr peptide derivatives 16-19.

A second type of fullerenyl amino acid was initially envisaged as a methanofullerene of the type 21
(Scheme 4). Strategies towards such molecules include the addition of diphenyliminoglycinates to
[60]fullerene under Bingel cyclopropanation reaction conditions which was originally reported to
furnish the corresponding methano[60]fullerene derivatives 21 (Scheme 4).8 However subsequent
extensive NMR studies revealed that the structure of the products was that of the
dihydrofullerenoproline derivatives8b 22, and not the more strained three-membered (cyclopropane)
ring products 21. The dihydrofullerenoproline derivative 22b was hydrolysed to its carboxylic acid
using TFA yielded 23 in 90% yield.

Scheme 4: The addition of iminoglycinate to [60]fullerene under Bingel cyclopropanation reaction conditions provides
the analogous [60] dihydrofullerenoproline derivative 22, with a proposed mechanism, and not the previously reported
methano[60]fullerene 21.

The diacid9 25 (Scheme 5) was synthesised from the previously reported bis-adduct 248b by
hydrolysing the diester functionality with (CH3)3SnOH or BBr3 in 65% and 50% yields respectively.
This diacid 25 has been used to synthesise potential biologically useful fullerene amino acid
derivatives.

Scheme 5: Synthesis of diacid 25.

BF3.Et2O and NaCNBH3 mediated reductive ring-opening of the dihydrofullerenoproline
derivative8b 26 yields ethyl N-benzhydrylfullerenyl[60]glycinate 27, which was N-deprotected to
give ethyl fullerenylglycinate10 28, a true fullerenyl α-amino ester, which was fully characterized as
its more stable N-acetyl derivative 29. Therefore, the original structure 26 could be considered as a
protected version of 28. The free amine of 28 reacted with a variety of aldehydes and ketones in a
Mannich-type process to produce 5-substituted and 5,5-disubstituted fullerenoprolines 30-40. This
process represents a versatile and general strategy to synthesise fullerenoprolines.

Scheme 6: Synthesis of 5-substituted and 5,5-disubstituted fullerenoprolines 30-40.

The reactions of amino acid ester hydrochlorides and CS2 with [60]fullerene in the presence of Et3N
yields novel [60]fullerene derivatives 42 (major) and 43 (minor) containing biologically active
amino acids,11 thioamide, and thiourea units. The thiolactam groups in compounds 42 are sensitive
to moisture and can easily be hydrolyzed to the corresponding lactams.

Scheme 7: Reactions of [60]fullerene with amino acid esters and CS2.

2 Synthesis of [60]fullerenyl N-Capped Peptides and Amino Acids
The thermal addition of the diazomethane derivative 44 to [60]fullerene and subsequent
deprotection of the ester of the resulting methano[60]fullerene 45 provided the acid 46.12 This
represented the first synthesis of a fullerenyl compound which had a synthetic handle to readily
allow for peptide functionalization (Scheme 8). The acid 46 was converted to the reactive acid

chloride 47 which underwent amide coupling with a pentapeptide under basic conditions to provide
the first reported fullerenyl peptide 48.12

Scheme 8: Synthesis of 48 through a diazo-addition of 44 to [60]fullerene.

This work was extended to alkyl diazoacetates of the type 49, which was added to [60]fullerene
forming the methano[60]fullerene 50, which was deprotected to the carboxylic acid 51 and then
coupled to amino acids under standard DCC coupling reaction conditions to form fullerenyl amino
acid esters of the type 52.13 Alternatively, a more efficient route was developed, that allowed the
direct addition of diazoamides to [60]fullerene. For example, a solution of [60]fullerene in toluene
was treated with the diazoamide 50 at reflux for 48 h providing the fullerenyl amino acid 53 (R =
Bn) in 30% yield (Scheme 9).14

Scheme 9: Synthesis of 51 through a diazo-addition of 49 or 53 to [60]fullerene.

Thermal reactions of [60]fullerene with other diazo compounds such as diazomethanes,15
diazoacetates,16 diazoamides, diazomethylphosphonates,17 and diazoketones, provides a broad
variety

of

methano[60]fullerenes,

having

handles

for

further

functionalization.

The

methano[60]fullerene 51 can be accessed from either the tert-butyl ester 54 (Scheme 10) or the Oglycolic ester 49 (Scheme 9), followed by ester deprotection of the fullerenyl adducts 55 and 50,
respectively. The synthetic utility of the methano[60]fullerenyl carboxylic acid 51 was
demonstrated by its DCC/HOBt mediated amine coupling with peptides to produce the fullerenyl
peptides 56 and 52.18

Scheme 10: Synthesis of peptide 56 was achieved through addition of 54 to [60]fullerene. i) H-Thr-Thr-Asn-Tyr-ThrOH, DCC, HOBt, C6H5Br/DMSO (6:1).

The Bingel reaction conditions have been modified to work, in moderate to excellent yields, with
ketones, esters and iminoglycinates. This modification has allowed for the generation of the
analogous α-haloanion in situ rather than the previous isolation of the halogenated intermediate.19
This efficient and reliable one-pot reaction has been used extensively with malonic esters 57 and
derivatives, as illustrated in Scheme 11.19a, 20
O
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Scheme 11: Malonates add to [60]fullerene under Bingel cyclopropanation conditions to provide methanofullerenes 58.

Thermolysis of sulfones 59 in the presence of [60]fullerene in 1,2,4-trichlorobenzene at reflux
under a nitrogen atmosphere afforded the fullerene derivatives 60 (via the corresponding pyrimidine
o-quinodimethanes) (Scheme 12). A similar reaction with 61 did not give the expected adduct but
the dehydration product 63 (Scheme 12).21 Acetylation of 61 to 62 before the cycloaddition reaction
did not prevent the formation of compound 63.

Scheme 12: Synthesis of [60]fullerene based tetrahydroquinazolines.

Organic azides act as 1,3-dipoles and can undergo [3+2]-cycloaddition reactions (either
photochemically or thermally) with [60]fullerene to yield fulleroaziridines (Scheme 13).22 Of these
organic azides, photochemical or thermal reactions of [60]fullerene with perfluorophenylazide 64
produces the fulleroaziridine 65 with an activated N-hydroxysuccinamide ester. This active ester
allows further functionalization, such as peptide coupling resulting in the formation of 66.

Scheme 13: Synthesis of fulleroaziridine.

The reaction of [60]fullerene with organolithium and Grignard reagents have been exploited to
incorporate a protected carboxylic acid functionality onto the C60 sphere.23 The organometallic
reagent made from the stable bicyclic orthoester 67, prepared by following the general procedure
described by Corey,24 has been successfully added to [60]fullerene to give adduct 68. This was
converted to the acid 70 by two sequential hydrolysis steps and then coupled with L-alanine ethyl
ester hydrochloride to give 71 (Scheme 14).

Scheme 14: Synthesis of 1-hydro-2-[3ʹ-(L-Ala-OEt)propyl]-1,2-dihydro[60]fullerene 71.

Methano[60]fullerene carboxylic acid derivatives 51 and 72-74 were converted to their active esters
of N-hydroxysuccinimide (NHS) 75-78 and pentafluorophenol (PFP)25 79-82 and coupled with
amino acids and peptides. These active esters have been reacted selectively with the amine group of
the amino acid or peptide, or the hydroxy group but only under DMAP catalysis.

Scheme 15. Derivatization of 51 and 72-74 with amino acids and peptides.

3 Synthesis of [60]Fullerenyl C-Capped Peptides and Amino Acids
Alternative methods to generate methano[60]fullerene derivatives via addition/elimination
mechanisms have employed sulfonium and phosphonium ylides.26 Deprotection of the ester
moieties in these methano[60]fullerenes, as well as the malonate derivatives, has provided access to
versatile handles, including the carboxylic acid 51 which was generated by the addition of the
sulfonium ylide 87 to [60]fullerene, followed by cleavage of the tert-butyl ester 55 with p-TsOH
(Scheme 16).27 The acid 51 was then converted to its acid chloride 88, which was subsequently
treated with tributyltin azide to deliver the acyl azide 89 in good yield. Exposure of 89 to o-xylenes
at reflux was expected to have afforded the isocyanate 90, which was not isolated but trapped as the
tert-butyl carbamate derivative 91. Treatment of 91 with TfOH provided the amine salt 92, which

was coupled to various acyl chlorides 93 to generate the corresponding amide derivatives 94
(Scheme 16).28

Scheme 16: Synthesis of amides 94 was achieved through a Curtius rearrangement.

Thermal ring opening of methylenecyclopropanone ketal 95 in chlorobenzene in the presence of
[60]fullerene followed by silica gel hydrolysis of the resulting ketene acetal gave a mixture of
cycloadducts 96 and 97.29 The corresponding fullerenyl amino ester derivatives 98 and 99 were
subsequently prepared from 96 by DCC coupling (Scheme 17).30

Scheme 17: Synthesis of fullerenyl amino ester derivatives via [3+2]-cycloaddition reactions.

Protected bis-fulleropyrrolidine amino acids derivatives 103 and 104 have been synthesised and
characterised from two successive [3+2]-cycloaddition reactions of azomethine ylides to
[60]fullerene, prepared in situ from the reactions of N-glycine derivatives and formaldehyde (Prato
reaction). These reactions resulted in two different fullereopyrrolidine couples having
unsymmetrical, orthogonally protected amino and acid functional groups.31 These peptides could be
used as models for fullerene-based peptidomimetics with the carbon sphere inserted into the peptide
backbone (Scheme 18).

Scheme 18: Synthesis of mono-fulleropyrrolidines and unsymmetrical bis-fulleropyrrolidines.

The 1,3-dipolar cycloaddition reaction of the N-substituted glycine derivative 105 to [60]fullerene
produced the fulleropyrrolidine 106 having a hydroxyl group at the terminus of the N-substituent
(Scheme 19). Subsequent esterification of this alcohol with the C-terminus of the protected amino
acids gave 107 and 108. Deprotection of 108 to its TFA salt 109 and then coupling with a
hexapeptide followed by final deprotection with TFA resulted in the fullereno peptide 110, having
an oxidised methionine residue.32

Scheme 19: Synthesis of [60]fulleropeptides.

4 Synthesis of Fullerenyl Amino Acids That Could Potentially be Incorporated
into Peptide Chains
The synthesis of highly functionalized benzo-annulated indane-based α-amino acid (AAA)
derivatives was reported via a [4+2]-cycloaddition strategy using the sultine derivative 111,
containing an AAA ester moiety, as a reactive diene component. By adopting this strategy, a new
α,α-dialkylatedindane-based [60]fullerene containing a rigid AAA unit 112 was realized (Scheme
20).33

Scheme 20: Synthesis of α,α-dialkylatedindane-based [60]fullerene containing AAAs.

A Diels-Alder approach has been developed to prepare dicarba analogues of cystine. Treatment of
diene 113 with [60]fullerene in toluene at reflux furnished the stable cycloadduct 114 in good yield
(Scheme 21).34

Scheme 21: [60]Fullerene-based dicarba analogue of cysteine 114

Ketone 117 has been used to synthesise [60]fullerene substituted D-phenylalanine derivatives
(Scheme 22).3d The para-amino substituted phenylalanine derivatives 115 and 116 readily undergo
condensation reactions with 117 forming the analogous imines 118 and 119, which were converted
to their corresponding amines 120 and 121 by borane reduction. The N-Boc-glycine derivative 120
was coupled to ethyl glycinate under HBTU mediated coupling conditions to provide the peptide
122. Treatment of the methyl glycinate derivative 121 with BBr3 led to the isolation of the free
glycine analogue 123.

Scheme 22: Synthesis of [60]fullerenyl amino acids 122 and 123.

A rhodium catalyzed reaction of [60]fullerene with the boronic acid derivative of phenylalanine 124
is shown in Scheme 23. This reaction gave the fullerene-tagged amino acid 125 in 47% yield.35

Scheme 23: Synthesis of 1-substituted 1,2-dihydro[60]fullerene derivatives.

A direct route was developed to produce fullerenyl peptides 127 by prolonged thermolysis of
various diazoamides (e.g. 126) in the presence of [60]fullerene (Scheme 24).14

Scheme 24: Thermal addition of diazoamide to [60]fullerene provides direct access to fullerenyl amino esters.

[60]Fullerene functionalized amino acids with 4–6 methylene spacers from the α-carbon to the
nitrogen atom of fulleropyrrolidine 128, and their corresponding fullerene peptides 130, have been
synthesized from the reactions of N-glycine derivatives, formaldehyde and [60]fullerene under
Prato’s reaction conditions as shown in Scheme 25.36

Scheme 25: Synthesis of [60]fullerene functionalized amino acids with 4-6 methylene spacers.

The [4+2]-cycloaddition of the 2-silyloxybutadiene 131 to [60]fullerene provided the ketone 117,
after hydrolysis. Subsequent reduction with DIBAL-H afforded the racemic alcohol 132, a versatile
synthon for the generation of fullerenyl amino acid derivatives (Scheme 26). For example, the DCC
mediated esterification of 132 with alanine and glutamate derivatives provided the protected
fullerenyl amino acids 133.3c

Scheme 26: Synthesis of [60]fullerenyl amino acid 133.

[60]Fullerene pyrrolidine derivative (139), bearing two carboxylic acid functional groups has been
reported (Scheme 27).37 The crucial glycine precursor 137, was synthesised from commercially
available starting materials and reacted with [60]fullerene and formaldehyde under Prato’s reaction
conditions to yield the diester 138. The tert-butyl groups of 138 were deprotected under acidic
conditions, which eﬃciently provided the stable bis-acid derivative 139. This diacid derivative was
readily functionalized under solid phase conditions to yield the derivatives dipeptide 140 and PEG
141. In addition, the reaction of 138 with TFA and TFAA provide an anhydride intermediate, which
was used to synthesise [60]fullerene derivatives bearing two different amide moieties 142.

Scheme 27. Synthesis of Bis-carboxylic acid group functionalized [60]fullerene derivatives.

The [60]fullerene derivative 143 was deprotected with TFA to give a free amino functional linker
containing [60]fullerene derivative 144. This was then reacted with N-Fmoc-L-glutamic acid α-tertbutyl ester to yield a [60]fullerene functionalized amino acid. The tert-butyl ester was deprotected
under acidic conditions to give the carboxylic acid 145, and this acid was subjected to solid-phase

peptide synthesis with peptide 146. The product 147 was cleaved from the resin support and was
found to be was water soluble.38

Scheme 28: Solid phase synthesis of fullereno peptide 147.

Applications of [60]fullerene amino acids and peptides
The potential uses of amino acid and peptide derivatives of fullerenes range from the biological to
the material sciences. This section will outline the major areas of achievement.
Biological Applications
The product 110 was biologically active against sera from Mixed Connective Tissue Disease
(MCTD) and Systemic Lupus Erythematosus (SLE) patients (ELISA experiments).32
The peptide 146 itself was not acitive against Staphylococcus aureus (S. aureus) and Escherichia
coli (E. coli), whereas the analogous [60]fullerenopeptide 147 showed antimicrobial activity against
S. aureus and E. coli (Table 1 ).38
Table 1. Antimicrobial Activity of Peptides 146 and 147, Reported as MIC (Minimum Inhibitory Concentrations).
Results are the mean of a minimum four independent evaluations run in duplicate (na = nonactive).
Peptide

146

147

S. aureus

na

8 µM

E. coli

na

64 µM

The antioxidant properties of the water soluble amino acid derivatives of the sodium salts of
fullerenylaminobutyric acid (C60-γ-ABNa, 148) and fullerenylaminocaproic acid (C60-ω-ACNa,
149) as well as that of the hybrid structure based on a N-fullerenoproline and the natural oxidant
carnosine (C60-Pro-carnosine, 150) (Figure 1) have been studied. Their roles in the inhibition of
herpes virus infection have also been described.39 The amino acid fullerene derivatives 148 and 149
of [60]fullerene were found to have significant antioxidant activities and were not cytotoxic (IC50
1000 and 1200 μg mL–1 (mln. cells), for 149 and 148, respectively). These derivatives were also
studied as inhibitors of cytomegalovirus infection (CMVI). The introduction of C60-γ-ABNa 148,
into infected human embryonic fibroblasts (HEF) reduced the concentration of virus proteins in the
cells to values approaching that in non-infected cells (Table 2). The malonic dialdehyde (MDA)
concentration in the infected HEF culture also decreased to the concentration in intact HEF. The
drug ganciclovir also decreased the lipid peroxidation (LPO) level in the HEF culture but had
significantly lower antioxidant and inhibitory effects than 148 (Table 2). These results indicated that
the antioxidant activity of these fullerene derivatives played an important role in their antiviral
effect against CMVI. Compound 148 was considered as a potential chemotherapeutical drug against
CMVI. Its chemotherapeutical index (CTI) was found to be 5000, which fivefold exceeds that of
ganciclovir.
Table 2. Contents of the protein and MDA in the HEF cultures
Sample

Protein content
/mg (mln.
cells)–1
0.07±0.02
0.284±0.03
0.22±0.04

[MDA].10–5
/mol.L–1(mln.
cells)-1
3.75±0.03
6.8±0.01
5.4±0.03

HEF
HEF-CMV
HEF-CMVgancyclovir
HEF-CMV-C60-γ0.072±0.02
3.8±0.03
ABNa (148)
Note. The concentration of ganciclovir and C60-γ-ABNa 148, in the cell culture was 2.10–5mol L–1(mln. cells)–1. The
average values of five measurements were presented.

Figure 1: [60]Fullerene based water soluble amino acids.

As part of an ongoing antibacterial drug research project a series of mono substituted and
disubstituted peptide fullerene derivatives (Figure 2) were synthesised.9 These were prepared from

the acid 23 and diacid 25, respectively. Although these derivatives did not show any substantial
anti-bacterial activity, their synthesis has progressed the development of the important field of
fullerenyl amino acids and peptide derivatives, in particular, their synthesis and isolation as peptide
salts (156-160) and the high incorporation of basic amino acids with side chains. This is highlighted
by the reasonable solubility of the deprotected compounds (156-160) in DMSO/water and the
relative ease of purification of the protected fullerenyl peptides (151-155 and 161) by column
chromatography. Further, these fullerenyl amino acids have a more rigid, and thus more defined,
tethered structure than many other fullerenyl peptides reported, which traditionally employ a
flexible fullerene-peptide linker. These more rigid properties could become increasingly important
in the fields of medicinal chemistry or materials science.

Figure 2: [60]Fullerene based novel peptides (151-155 and 161) and dicationic peptoids (156-160).

Antioxidative/anti-inflammatory activity of the fullerene-polyamine (FUL-PA) conjugates 162-169
has been described.40 Conjugation of [60]fullerene with spermine (SPM) or spermidine (SPD)
resulted in a large improvement of both the anti-lypoxygenase (LOX) and the anti-lipid
peroxidation activity of the unconjugated molecules. An enhancement in the anti-inflammatory
potency of [60]fullerene was observed only with the conjugate 163 (42%), which was comparable
in activity to the reference compound indomethacin (47%). Most of the FUL-SPD conjugates, and
especially compounds 163 and 165 were of comparable toxicity, even at the highest concentration
tested (50 mM), therefore they could be potentially safely used for possible biomedical
applications.40

Figure 3: Biologically active novel fullerene-polyamine (FUL-PA) conjugates.

The glycopeptide antibiotic derivative teicoplanin ψ-aglycone has been covalently attached to a
fullerenopyrrolidine derivative using azide-alkyne “click chemistry”. The aggregation of the
resulting antibiotic-fullerene conjugate 170 in aqueous solution has been studied resulting in nanosized clusters.41 The conjugate exhibited antibacterial activity against Enterococci resistant to
teicoplanin (Table 3).
Table 3. Antibacterial activity of compound 170.
Bacteria

Teicoplanin

Compound 170

MIC (µg/mL)
16
8
4
2

B. subtilis ATCC 6633
0.5
S. aureus MSSA ATCC 29213
0.5
S. aureus MRSA ATCC 33591
0.5
S. epidermidis
4
ATCC 35984 biofilm
S. epidermidis mec A
16
1
E. faecalis ATCC 29212
1
6
E. faecalis 15376 VanA
256
16
E. faecalis ATCC 51299 VanB
0.5
16
Note. MIC: Minimum Inhibition Concentration, ATCC: American Typed Culture Collection, B. subtilis, Bacillus
subtilis; E. faecalis, Enterococcus faecalis, MRSA: Methicillin Resistant Staphylococcus aureus, vanA : vanA gene
positive, vanB : vanB gene positive.

Figure 4: Teicoplanin ψ-aglycon-fullerene conjugate 170.

The water-soluble dendrofulleropyrrolidine 171 (synthesised from 101) and its bis-analogues 172
and 173 have been prepared.42 These cationic species can efficiently complex plasmid DNA as
demonstrated by gel electrophoresis studies. These molecules showed excellent DNA binding
efficiencies and were therefore considered to be potential candidates for DNA binding therapies.

Figure 5. Monoadduct 171 and bis adducts 172 and 173 of highly water soluble polycationic [60]fullerenes.

The fulleropyrrolidine peptides containing only GABA (γ-aminobutyric) residues, having zero or
one glycine moiety have been reported (Figure 6).43 The authors claim that these may be used as
nanobioparticles. However, no results related to these properties were reported.

Figure 6. Fulleropeptides 175-185 synthesized from fulleropyrrolidinic acid 174.

Mitsutoshi et. al. reported the inhibitory effects of [60]fullerene derivatives 186 ([60]fullereneproline-N-acetic acid) and 187 ([60]fullerene-ethylenediamine-N,Nʹ-diacetic acid) on acetylcholineinduced (endogenous NO) relaxation in endothelium-intact rabbit thoracic aorta precontracted by
phenylephrine (10-6 M).44 The [60]fullerene derivatives 186 (10-5 M) and 187 (10-5 M) reduced the
maximum amplitude of the acetylcholine-induced relaxation without significantly changing the pD2
values obtained from the concentration response curves.

Figure 7. [60]Fullerene derivatives 186 ([60]fullerene-proline-N-acetic acid) and 187 ([60]fullerene-ethylenediamineN,Nʹ-diacetic acid).

Water soluble [60]fullerene derivatives 188-190 (WSFD), have been studied to show the potential
to prevent NO-induced cytotoxicity without obvious toxicity.45 These fullerene derivatives apply
protective activities by direct interaction with NO and neutralization of O2-. The folacin fullerene
derivative 190 (FFD) self-assembles to form spherical aggregates because of hydrogen bonding,
and the aggregate ion morphology impacts on the NO-scavenging activities of the WSFD.
Pretreatment of the cells with WSFD prior to the sodium nitroprusside (SNP) exposure blocks NOinduced cellular events including oxidation of membrane lipids, depolarization of mitochondrial
membranes, reduction of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidise
(GSH-Px) activities and caspase-mediated apoptotic cell death. Apart from the biological studies,
the authors have revealed the synthesis of novel fullerene derivatives with anti-apoptotic
properties.45, 46

Figure 8. Chemical structures of (188) AFD, (189) VFD and (190) FFD.

Oxidized [60]fullerene glutathione derivatives have been synthesized and characterized.46,47 The
[60]fullerene glutathione derivative 192 was soluble in dimethylsulfoxide, dimethylformamide and
dimethylacetamide. Rat pheochromocytoma (PC12) cells were treated with hydrogen peroxide,
cytotoxicity and apoptotic death was estimated by the MTT assay, flow cytometry analysis,
PI/Hoechst 33342 staining and glutathione assay. These results indicated that the glutathione
[60]fullerene derivative 192 has the potential to prevent oxidative stress-induced cell death without
toxicity.46

Figure 9: Cystein (191) and oxidized glutathione (192) [60]fullerene derivatives.

Materials Chemistry Applications
A new class of peptide nanotubes from α,γ-cyclic peptides (CPs) 193 tethered to a methanofullerene
moiety have been reported.48 These CPs are able to form nanotubes in which the fullerenes point
outward from the nanotube on both sides (180° orientation). The fullerenes form two parallel wires
separated by the insulating peptide nanotube. The authors suggest that these materials may have
applications as nanowire components and/or in optical and electronic devices.

Figure 10: Structure of tethered α,γ-cyclic peptide (CP) 193.

Two molecules having a pyrrolidino[60]fullerene tethered through an intramolecular hydrogen
bonding peptide linker to a nitroxide radical have been synthesised.49 These peptide moieties have
rigid 310-helical structures that possess a strong molecular dipole. The direction of the molecular
dipole moment can be reversed by switching the position of fullerene and nitroxide with respect to
the peptide nitrogen and carbon terminus. The fullerene-peptide-radical systems 194 and 195 were
compared to the behaviours of otherwise identical peptides but without either [60]fullerene or the
free radical moiety with retaining the same number of intramolecular hydrogen bonds.

Figure 11: Structures of [60]fullerene based peptides with intramolecular hydrogen bonds and dipole moments
illustrated.

A strategy of photocurrent generation out of thin layers composed by the amphiphilic [60]fullerene
and pyrene derivatives was investigated by Shunsaku’s group.50 Three different types of compounds
namely [60]fullerene-cyclic peptide-PEG conjugate 198 (cyclo8-C60-PEG), [60]fullerene-PEG
conjugate 197 (C60-PEG) without a cyclic peptide scaffold, and the pyrene derivative 196 (R-Pyr)
having a diethylene glycol and a long alkyl chain were synthesised. The study of photoinduced
electron transfer concluded that a bilayer structure with desired orientation of functional units is
important for efficient photoinduced electron transfer and that cyclic peptide scaffold is useful to
locate hydrophobic functional groups in a thin layer.

Figure 12: Chemical structures of R-Pyr 196, C60-PEG 197 and cyclo8-C60-PEG 198.

[60]Fullerene amino acid monomer 199 and the bis-fullerene 200 been studied experimentally using
spectroelectrochemical measurements. The bis-fullerene-substituted peptide51 200 provided
experimental support for density-functional theory (DFT) calculations which indicate that van der
Waals fullerene dimers can form between adjacent fullerenes in semiconductor layers resulting in
interstitial electron traps. The fullerenes behave like “super atoms” and the interstitial electron traps
represent one-electron intermolecular σ-bonds. The proposed electron traps are relevant for all
organic electronics applications in which non-covalently linked fullerenes in van der Waals contact
with one another are used as n-type semiconductors.52
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Figure 13: Structures [60]fullerene amino acid monomer 199 and bis-fullerene 200.

The stereoselectivity of the formation of hybrid amino acid derivatives of fullerene (AADF) C60
was studied by Dolinina et. al.53 The energies of the model addition reactions of two different
reactions were calculated by the DFT method B3LYP/631G*. The most stable products of these
reactions are hexamethylated fullerene derivatives in which five Me groups are arranged in the form
of a regular pentagon and AADF. Among the AADF obtained by reactions, 1,4-disubstituted

fullerene isomers are most stable. The molecular structures of such isomers were calculated for six
biologically active hybrid AADF’s 201-206 (Figure 14); the solvent contact areas of these
molecules were evaluated (Table 4).

Figure 14: Structures of AADF 201-206.

Table 4. Calculated water contact areas (S/Å2) of hybrid AADFa
Stot(Sful)b
Entry
X
Y
C60
530 (530)
C2H4OH
Me
711 (443)
201
C2H4ONO2
Me
783 (440)
202
C2H4OH
CH2ONO2
818 (437)
203
C2H4ONO2
CH2ONO2
831 (412)
204
CH2CH(NO3)CH2NO3 (S)
Me
838 (423)
205
C2H4-carnosine
Me
968 (406)
206
a The equilibrium conformations were calculated at the B3LYP/631G*//B3LYP/631G* level.
b Stot and Sful are the contact areas of the whole molecule and the fullerene fragment, respectively. The radius of the
sphere of the water molecule is 1.4 Å.

Induction of optical activity of fullerene C60 by covalently bound amino acid moieties and peptide
fragments (207-215) was studied by Babievsky et. al.54 using optical circular dichroism (CD)
(Table 5). Significant asymmetric induction transfer was found when a stereogenic atom is adjacent
to fullerene cage.54

Figure 15: Structures of compounds 207-215.

Table 5. Circular dichroism spectra of fullerene derivatives 207-215.
Entry

M

207
208
209
210
211
212
213
214
215

847
823
918
904
874
918
867
937
1027

C.103
/mol L-1
1.77
2.43
1.04
1.77
1.80
0.44
0.35
1.82
0.30

ΔA. 10-6
(rel. units)
350
370
330
180
150
78
123
155

λmax
/nm
530
540
556
550
450
505
460
499

Δε 10-2
/mol L-1 cm-1
19.7
15.2
10.1
32.0
34.0
22.3
6.7
51.6

Investigation of energy transfer interactions between C60 fullerenes and four different quantum dots
(QDs), composed of CdSe/ZnS (type I) and CdSe/CdS/ZnS (quasi type II), with emission maxima
ranging from 530 to 630 nm was performed by Stewart et. al.55 C60-pyrrolidine tris-acid was first
coupled to the N-terminus of a hexahistidine terminated peptide via carbodiimide chemistry to yield
a C60-labeled peptide 216 (pep-C60). This peptide was studied for the ratiometric self-assembly of
the QD-(pepC60) nanoheterostructures by exploiting metal affinity coordination to the QD surface.
Photoinitiated energy transfer and competition between electron transfer and Förster resonance
energy transfer from the QD to the C60 were also studied with the aim of potential use in
optoelectronic and biosensing applications.55

Figure 15: Structure of C60-labelled peptide 216.

Conclusions
In conclusion, fullerenyl amino acids and related derivatives have been classified into functional
types for different uses: these include directly attached fullerenyl amino acids, fullerenyl N- and Ccapping amino acids, and those amino acids in which the [60]fullerene group is attached to the
amino acid side chain. These first and last mentioned derivatives have the potential to be
incorporated into non-terminal positions of peptides. The applications of these substrates, by
integration into different biological and materials chemistry programs, have also been highlighted.
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